ArticleClinical lipidology2011
Management of dyslipidemia in HIV-infected patients.
Article in Clinical lipidology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.AIDS research and human retroviruses · 2013Trial
- Service delivery interventions for lipid testing and lipid-lowering therapy for primary and secondary prevention of cardiovascular disease in adults.The Cochrane database of systematic reviews · 2026Article
- Latent Profile Analysis of Disease Self-Management and Its Associated Factors Among People Living with HIV with Dyslipidemia.Patient preference and adherence · 2026Article
- Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy.The Journal of antimicrobial chemotherapy · 2025Article
- Optimizing statin therapy in HIV-infected patients: a review of pharmacotherapy considerations.BMC cardiovascular disorders · 2025Review
- Article
- Article
- The Incidence and Risk Factors of Renal Insufficiency among Korean HIV infected Patients: The Korea HIV/AIDS Cohort Study.Infection & chemotherapy · 2022Article
- Atherosclerosis in HIV Patients: What Do We Know so Far?International journal of molecular sciences · 2022Review
- Immunosuppression and HIV Viremia Associated with More Atherogenic Lipid Profile in Older People with HIV.AIDS research and human retroviruses · 2019Observational
- Factors affecting high-density lipoprotein cholesterol in HIV-infected patients on nevirapine-based antiretroviral therapy.The Indian journal of medical research · 2017Article
- Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.HIV/AIDS (Auckland, N.Z.) · 2017Article
- Changes in coronary heart disease risk profiles of HIV patients in Zimbabwe over 9 months: a follow-up study.HIV/AIDS (Auckland, N.Z.) · 2016Article
- The lipid profile of HIV-infected patients receiving antiretroviral therapy in a rural Cameroonian population.BMC public health · 2014Article
- Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects.AIDS research and therapy · 2013Article
- HIV stroke risk: evidence and implications.Therapeutic advances in chronic disease · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Antiretroviral therapy has dramatically increased survival for HIV-infected individuals. As this population lives longer, coronary heart disease has become an important comorbid condition. Dyslipidemia in HIV-infected individuals is a complex condition, with multiple contributing factors including the HIV virus itself, individual genetic characteristics and antiretroviral therapy-induced metabolic changes. Effective management of dyslipidemia in this population is essential to reduce cardiovascular risk but presents multiple challenges due to interactions between antiretroviral therapy agents and lipid-lowering medications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.